Market capitalization | $18.53b |
Enterprise Value | $16.92b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.10 |
P/S ratio (TTM) P/S ratio | 5.59 |
P/B ratio (TTM) P/B ratio | 5.90 |
Revenue growth (TTM) Revenue growth | 50.46% |
Revenue (TTM) Revenue | $3.32b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
33 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:
33 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:
Sep '24 |
+/-
%
|
||
Revenue | 3,317 3,317 |
50%
50%
|
|
Gross Profit | 2,656 2,656 |
49%
49%
|
|
EBITDA | -727 -727 |
40%
40%
|
EBIT (Operating Income) EBIT | -873 -873 |
32%
32%
|
Net Profit | -860 -860 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
Head office | Cayman Islands |
CEO | John Oyler |
Employees | 10,000 |
Founded | 2010 |
Website | www.beigene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.